Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more
Scandion Oncology A/S (SCOL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.220x
Based on the latest financial reports, Scandion Oncology A/S (SCOL) has a cash flow conversion efficiency ratio of -0.220x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.82 Million) by net assets (Skr8.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scandion Oncology A/S - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scandion Oncology A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scandion Oncology A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Renewi PLC
LSE:RWI
|
0.336x |
|
Hilong Holding Limited
PINK:HLONF
|
N/A |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
0.014x |
|
Bytes Technology Ltd
LSE:BYIT
|
0.132x |
|
MRWNS
OTCGREY:MRWNS
|
N/A |
|
Icon Energy Limited
PINK:ICNOF
|
0.072x |
|
UESTRA
BE:HVB
|
N/A |
|
Qutoutiao Inc.
PINK:QTTOY
|
N/A |
Annual Cash Flow Conversion Efficiency for Scandion Oncology A/S (2017–2024)
The table below shows the annual cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr8.27 Million | Skr-27.52 Million | -3.328x | -104.45% |
| 2023-12-31 | Skr31.12 Million | Skr-50.67 Million | -1.628x | -64.88% |
| 2022-12-31 | Skr70.33 Million | Skr-69.44 Million | -0.987x | -107.29% |
| 2021-12-31 | Skr104.54 Million | Skr-49.80 Million | -0.476x | -325.45% |
| 2020-12-31 | Skr155.87 Million | Skr-17.45 Million | -0.112x | +79.38% |
| 2019-12-31 | Skr18.34 Million | Skr-9.96 Million | -0.543x | +48.59% |
| 2018-12-31 | Skr12.57 Million | Skr-13.28 Million | -1.056x | -28.93% |
| 2017-12-31 | Skr1.45 Million | Skr-1.19 Million | -0.819x | -- |